Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
15 nov. 2024 06h00 HE
|
Sanofi - Aventis Groupe
Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland Lyon, le 15 novembre 2024 –...
Communiqué de presse - Aadil BEZZA rejoint Sanofi comme Directeur des Ressources Humaines France
12 nov. 2024 04h00 HE
|
Sanofi - Aventis Groupe
Aadil BEZZA rejoint Sanofi comme Directeur des Ressources Humaines France Paris, le 12 novembre 2024. Sanofi annonce la nomination d’Aadil BEZZA au poste de Directeur des Ressources Humaines France à...
Communiqué de presse - Sanofi obtient l’Autorisation de Mise sur le Marché d’Efluelda, son vaccin trivalent haute dose, pour la prochaine saison grippe 2025/2026
05 nov. 2024 04h02 HE
|
Sanofi - Aventis Groupe
Sanofi obtient l’Autorisation de Mise sur le Marché d’Efluelda, son vaccin trivalent haute dose, pour la prochaine saison grippe 2025/2026 Paris, 5 novembre 2024. L’ANSM vient...
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
09 sept. 2024 10h20 HE
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
24 juil. 2024 14h00 HE
|
Spherix Global Insights
EXTON, PA, July 24, 2024 (GLOBE NEWSWIRE) -- Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to autoantibodies. Among...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
18 juil. 2024 10h05 HE
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
12 juil. 2024 07h00 HE
|
FluGen, Inc.
Combining FluGen's M2SR nasal spray flu vaccine with Sanofi's Fluzone High Dose shot generates superior results in older adults versus the shot alone.
Antidiuretic Drugs Market Size & Share to Exceed USD 1504.8 Million by 2034, at CAGR of 11.5%. "Fluid Harmony: Navigating the Antidiuretic Drugs Market for Optimal Hydration Solutions" – PMI Leads the Way
01 févr. 2024 15h00 HE
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Antidiuretic Drugs Market size was valued at about USD 558.7 Million in 2024 and expected to grow at CAGR of...
The International Myeloma Foundation is Creating an Award-Winning Tool for Nurses to Improve Myeloma Patient Outcomes in Underserved Communities
02 nov. 2023 13h15 HE
|
International Myeloma Foundation
The International Myeloma Foundation wins the 2023 Sanofi HealthEquity Accelerator Award for their program which empowers nurses and tackles disparities.
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
14 sept. 2023 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...